Isomorphic Labs Raises $5B Series C to Take AI-Designed Drugs Into the Clinic
Five billion dollars, in one round, for a company that has not put a drug through a clinical trial yet. Isomorphic Labs, the drug-design spinout Google DeepMind created in 2021, closed a $5B Series C co-led by Greenoaks and Sequoia. a16z comes in as a new investor, and the existing backers are back: GV, CapitalG, Thrive, MGX, Temasek and the UK Sovereign AI Fund. No valuation was disclosed. TechCrunch: https://techcrunch.com/2026/11/17/isomorphic-labs-raises-5b-as-it-looks-to-take-drug-candidates-to-clinical-trials/ , tech.eu: https://tech.eu/2026/11/17/sequoia-and-greenoaks-lead-massive-5bn-series-c-funding-round-in-isomorphic-labs/
The business in plain terms: Isomorphic builds a model-driven engine, descended from AlphaFold, that predicts how molecules bind to proteins and proposes drug candidates. It sells that capability through partnerships with Lilly, Novartis and J&J, and it also runs its own pipeline. The new money goes to three things: moving its own candidates into clinical trials, expanding the engine, and covering more drug modalities.
Look at the cadence. $600M in March 2025, $2.1B in May 2026, now $5B six months later. That is a company raising like a frontier lab, not like a biotech. It is also the first raise since Demis Hassabis stepped back from running DeepMind to become its chairman.
The real test is coming. Until now Isomorphic sold a promise: AI picks better molecules faster. A clinical trial is the first grader that does not care how good the model looks on a benchmark. If the candidates hold up in humans, this round will look cheap. If they fail at the usual rate, the field learns that predicting structure was never the bottleneck.
← Back to all articles
The business in plain terms: Isomorphic builds a model-driven engine, descended from AlphaFold, that predicts how molecules bind to proteins and proposes drug candidates. It sells that capability through partnerships with Lilly, Novartis and J&J, and it also runs its own pipeline. The new money goes to three things: moving its own candidates into clinical trials, expanding the engine, and covering more drug modalities.
Look at the cadence. $600M in March 2025, $2.1B in May 2026, now $5B six months later. That is a company raising like a frontier lab, not like a biotech. It is also the first raise since Demis Hassabis stepped back from running DeepMind to become its chairman.
The real test is coming. Until now Isomorphic sold a promise: AI picks better molecules faster. A clinical trial is the first grader that does not care how good the model looks on a benchmark. If the candidates hold up in humans, this round will look cheap. If they fail at the usual rate, the field learns that predicting structure was never the bottleneck.
Comments